Molecular recognition with biological receptors: Structure-based design of thrombin inhibitors

Chimia

Volumn 54, Issue 11, 2000, Pages 633-639

  Betschmann, Patrick ^a   Lerner, Christian ^a   Sahli, Stefan ^a   Obst, Ulrike ^b   Diederich, François ^a  

^a ETH ZURICH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Molecular recognition; Non peptidic inhibitors; Pharmaceutical chemistry; Structure based design; Thrombin

Indexed keywords

EID: 0034354473     PISSN: 00094293     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. W.-D. Woggon, R.M. Wenger, Chimia 2000, 54, 9.
2. a) P. Wallimann, T. Marti, A. Fürer, F. Diederich, Chem. Rev. 1997, 97, 1567;
3. b) P. Wallimann, P. Seiler, F. Diederich, Helv. Chim. Acta 1996, 79, 779;
4. c) P. Wallimann, S. Mattei, P. Seiler, F. Diederich, Helv. Chim. Acta 1997, 80, 2368;
5. d) S. Mattei, P. Wallimann, B. Kenda, W. Amrein, F. Diederich, Helv. Chim. Acta 1997, 80, 2391;
6. e) T. Marti, B.R. Peterson, A. Fürer, T. Mordasini-Denti, J. Zarske, B. Jaun, F. Diederich, Helv. Chim. Acta 1998, 81, 109;
7. f) A. Fürer, T. Marti, F. Diederich, H. Künzer, M. Brehm, Helv. Chim. Acta 1999, 82, 1843;
8. g) A.E. Christian, H.-S. Byun, N. Zhong, M. Wanunu, T. Marti, A. Fürer, F. Diederich, R. Bittmann, G.H. Rothblat, J. Lipid. Res. 1999, 40, 1475.
9. a) S. Anderson, U. Neidlein, V. Gramlich, F. Diederich, Angew. Chem. 1995, 107, 1722; Angew. Chem. Int. Ed. Engl. 1995, 34, 1596;
10. a) S. Anderson, U. Neidlein, V. Gramlich, F. Diederich, Angew. Chem. 1995, 107, 1722; Angew. Chem. Int. Ed. Engl. 1995, 34, 1596;
11. b) U. Neidlein, F. Diederich, Chem. Commun. 1996, 1493;
12. c) A. Bähr, A.S. Droz, M. Püntener, U. Neidlein, S. Anderson, P. Seiler, F. Diederich, Helv. Chim. Acta 1998, 81, 1931;
13. d) J. Cuntze, L. Owens, V. Alcázar, P. Seiler, F. Diederich, Helv. Chim. Acta 1995, 78, 367;
14. e) D.K. Smith, F. Diederich, Chem. Commun. 1998, 2501;
15. f) D.K. Smith, A. Zingg, F. Diederich, Helv. Chim. Acta 1999, 82, 1225.
16. a) E. Martinborough, T. Mordasini Denti, P.P. Castro, T.B. Wyman, C.B. Knobler, F. Diederich, Helv. Chim. Acta 1995, 78, 1037;
17. b) P. Lustenberger, E. Martinborough, T. Mordasini Denti, F. Diederich, J. Chem. Soc., Perkin Trans. 2 1998, 747;
18. c) P. Lustenberger, R. Welti, F. Diederich, Helv. Chim. Acta 1998, 81, 2190;
19. d) B. Hinzen, P. Seiler, F. Diederich, Helv. Chim. Acta 1996, 79, 942;
20. e) R.J. Pieters, F. Diederich, Chem. Commun. 1996, 2255;
21. f) R.J. Pieters, J. Cuntze, M. Bonnet, F. Diederich, J. Chem. Soc., Perkin Trans. 2 1997, 1891.
22. S.H. Reich, S.E. Webber, Perspect. Drug Discovery Des. 1993, 1, 371.
23. E.A. Lunney, Med. Chem. Res. 1998, 8, 352.
24. K. Gubernator, H.-J. Böhm, in 'Structure-Based Ligand Design', Eds. K. Gubernator, H.-J. Böhm, Wiley-VCH, Weinheim, 1998, p. 1.
25. U. Obst, 'De Novo-Design und Synthese neuartiger, nichtpeptidischer Thrombin-Inhibitoren', ETH-Dissertation Nr. 12037, 1997.
26. a) C.U. Kim, W. Lew, M.A. Williams, H. Liu, L. Zhang, S. Swaminathan, N. Bischofberger, M.S. Chen, D.B. Mendel, C.Y. Tai, W.G. Laver, R.C. Stevens, J. Am. Chem. Soc. 1997, 119, 681;
27. b) C.U. Kim, W. Lew, M.A. Williams, H. Wu, L. Zhang, X. Chen, P.A. Escarpe, D.B. Mendel, W.G. Laver, R.C. Stevens, J. Med. Chem. 1998, 41, 2451;
28. c) M. von Itzstein, J.C. Dyason, S.W. Oliver, H.F. White, W.-Y. Wu, G.B. Kok, M.S. Pegg, J. Med. Chem. 1996, 39, 388.
29. a) U. Obst, V. Gramlich, F. Diederich, L. Weber, D.W. Banner, Angew. Chem. 1995, 107, 1874; Angew. Chem. Int. Ed. Engl. 1995, 34, 1739;
30. a) U. Obst, V. Gramlich, F. Diederich, L. Weber, D.W. Banner, Angew. Chem. 1995, 107, 1874; Angew. Chem. Int. Ed. Engl. 1995, 34, 1739;
31. b) U. Obst, D.W. Banner, L. Weber, F. Diederich, Chem. Biol. 1997, 4, 287;
32. c) U. Obst, P. Betschmann, C. Lerner, P. Seiler, F. Diederich, V. Gramlich, L. Weber, D.W. Banner, P. Schönholzer, Helv. Chim. Acta 2000, 83, 855.
33. B. Masjost, P. Ballmer, E. Borroni, G. Zürcher, F.K. Winkler, R. Jakob-Roetne, F. Diederich, Chem. Eur. J. 2000, 6, 971.
34. A.M. Silva, A.Y. Lee, S.V. Gulnik, P. Majer, J. Collins, T.N. Bhat, P.J. Collins, R.E. Cachau, K.E. Luker, I.Y. Gluzman, S.E. Francis, A. Oksman, D.E. Goldberg, J.W. Erickson, Proc. Natl. Acad. Sci. USA 1996, 93, 10034.
35. C. Romier, K. Reuter, D. Suck, R. Ficner, EMBO J. 1996, 15, 2850.
36. For approaches to inhibitors for MHC (major histocompatibility complex) class II proteins, see: L. Ducry, S. Reinelt, P. Seiler, F. Diederich, D.R. Bolin, R.M. Campbell, G.L. Olson, Helv. Chim. Acta 1999, 82, 2432.
37. M.F. Scully, in 'Essays in Biochemistry', Ed. K.F. Tipton, Portland Press, London, 1996, p. 17.
38. D. Voet, J.G. Voet, 'Biochemie', VCH, Weinheim, 1992.
39. a) H. Kubinyi, Pharm. Unserer Zeit 1998, 27, 158;
40. b) P.E.J. Sanderson, A.M. Naylor-Olsen, Current Med. Chem. 1998, 5, 289;
41. c) K. Menear, Current Med. Chem. 1998, 5, 457;
42. d) J.B.M. Rewinkel, A.E.P. Adang, Curr. Pharm. Design 1999, 5, 1043.
43. a) W. Bode, I. Mayr, U. Baumann, R. Huber, S.R. Stone, J. Hofsteenge, EMBO J. 1989, 8, 3467;
44. b) D.W. Banner, P. Hadváry, J. Biol. Chem. 1991, 206, 20085.
45. a) The F. Hoffmann-La Roche AG in-house program Moloc [19b] was used for most molecular modeling studies; b) P.R. Gerber, K. Müller, J. Comput. Aided Mol. Design 1995, 9, 251.
46. a) The F. Hoffmann-La Roche AG in-house program Moloc [19b] was used for most molecular modeling studies; b) P.R. Gerber, K. Müller, J. Comput. Aided Mol. Design 1995, 9, 251.
47. V. Pavone, G. De Simone, F. Nastri, S. Galdiero, N. Staiano, A. Lombardi, C. Pedone, Biol. Chem. 1998, 379, 987.
48. a) F. Markwardt, H. Landmann, P. Walsmann, Eur. J. Biochem. 1968, 6, 502;
49. b) D. Labes, V. Hagen, Pharmazie 1979, 34, 649.
50. a) The affinity of thrombin inhibitors was determined at F. Hoffmann-La Roche AG according to [22b,c]; b) K. Hilpert, J. Akkermann, D.W. Banner, A. Gast, K. Gubernator, P. Hadváry, L. Labler, K. Müller, G. Schmid, T.B. Tschopp, H. van de Waterbeemd, J. Med. Chem. 1994, 37. 3889;
51. a) The affinity of thrombin inhibitors was determined at F. Hoffmann-La Roche AG according to [22b,c]; b) K. Hilpert, J. Akkermann, D.W. Banner, A. Gast, K. Gubernator, P. Hadváry, L. Labler, K. Müller, G. Schmid, T.B. Tschopp, H. van de Waterbeemd, J. Med. Chem. 1994, 37. 3889;
52. c) R. Lottenberg, J.A. Hall, J.W. Fenton, C.M. Jackson, Thromb. Res. 1982, 28, 313.
53. S.D. Kimball, Blood Coag. Fibrinol. 1995, 6, 511.
54. Full experimental and analytical details of most compounds described in Section 3 are provided in [10c].
55. B. Staskun, O.G. Backeberg, J. Chem. Soc. 1964, 5880.
56. T.J. Tucker, W.C. Lumma, A.M. Mulichak, Z. Chen, A.M. Naylor-Olsen, S.D. Lewis, R. Lucas, R.M. Freidinger, L.C. Kuo, J. Med. Chem. 1997, 40, 830.
57. H. McAlonan, J.P. Murphy, P.J. Stevenson, A.B. Treacy, Tetrahedron 1996, 52, 12521.
58. F. Marcuzzi, G. Modena, J. Org. Chem. 1982, 47, 4577.
59. a) W. Eschweiler, Ber. Deutsch. Chem. Ges. 1905, 38, 880;
60. b) H.T. Clarke, H.B. Gillespie, S.Z. Weisshaus, J. Am. Chem. Soc. 1933, 55, 4571.
61. A. Pinner, F. Klein, Ber. Deutsch. Chem. Ges. 1877, 10, 1889.
62. a) P.R. Guzzo, M.J. Miller, J. Org. Chem. 1994, 59, 4862;
63. b) M.C. Pirrung, J.H.-L. Chau, J. Org. Chem. 1995, 60, 8084.